Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NKR-2 with 5-azacytidine in AML/MDS (EPITHINK)
NCT03612739Phase 1Withdrawn
- Sponsor
- Celyad Oncology
- Start
- Dec 2018
- Primary completion
- May 2019
- Modality
- CAR-T Cells
01
Overview
Phase 1, open-label trial of CAR-NKG2D in acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) (3 cohorts), sponsored by Celyad Oncology. Primary endpoint: Dose Limiting Toxicities at 6 months. Planned start Dec 2018; status: withdrawn.
02
Drugs
CAR-NKG2D
03
Conditions
acute myeloid leukemia (AML)myelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on NCT03612739.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03612739.